BIAF · Bioaffinity Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.35M | - | $1.45M | $1.27M | $1.85M | - | $2.35M | $2.40M | $2.41M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $349.7K | - | $330.6K | $311.4K | $367.4K | - | $274.5K | $402.4K | $393.6K | - |
| SG&A | $3.24M | - | $2.21M | $2.21M | $2.45M | - | $2.36M | $2.47M | $2.19M | - |
| Total Operating Expenses | $4.97M | - | $3.74M | $3.79M | $4.48M | - | $4.32M | $4.49M | $4.35M | - |
| D&A | $114.5K | - | $113.4K | $113.2K | $154.6K | - | $151.3K | $21.6K | $149.6K | - |
| Operating Income | ($3.62M) | - | ($2.29M) | ($2.52M) | ($2.63M) | - | ($1.97M) | ($2.09M) | ($1.95M) | - |
| Interest Expense | $14.7K | - | $5.4K | $10.5K | $23.6K | - | $21.6K | $1.4K | $23.6K | - |
| Income Tax | - | - | $3.2K | $29.0K | $8.7K | - | $2.6K | $5.4K | $3.7K | - |
| Net Income | ($3.63M) | - | ($5.05M) | ($4.06M) | ($2.66M) | - | ($2.00M) | ($2.11M) | ($1.96M) | - |
| EPS - Basic | ($0.81) | - | ($4.74) | ($0.17) | ($0.16) | - | ($0.16) | ($0.19) | ($0.20) | - |
| EPS - Diluted | ($0.81) | - | ($4.74) | ($0.17) | ($0.16) | - | ($0.16) | ($0.19) | ($0.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.10M | $6.45M | $7.67M | $802.8K | $444.7K | $1.11M | $756.6K | $801.3K | $2.45M | $2.82M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $77.9K | $53.5K | $35.2K | $44.0K | $38.8K | $27.6K | $25.4K | $29.8K | $9.5K | $18.5K |
| Accounts Payable | $836.2K | $761.9K | $940.8K | $1.17M | $1.38M | $987.3K | $782.9K | $848.1K | $384.0K | $604.8K |
| Current Assets | $4.34M | $7.57M | $8.61M | $1.67M | $1.86M | $2.70M | $2.55M | $2.68M | $3.93M | $3.97M |
| Total Assets | $7.95M | $10.96M | $11.55M | $4.75M | $5.55M | $6.51M | $6.55M | $6.66M | $8.05M | $8.22M |
| Current Liabilities | $3.18M | $2.91M | $2.36M | $2.59M | $3.42M | $3.10M | $2.49M | $2.33M | $1.77M | $2.25M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.28M | $3.68M | $2.64M | $6.89M | $4.11M | $3.91M | $3.43M | $3.22M | $2.79M | $3.37M |
| Stockholders' Equity | $3.66M | $7.28M | $8.90M | ($2.14M) | $1.44M | $2.60M | $3.12M | $3.43M | $5.26M | $4.86M |
| Retained Earnings | ($72.18M) | ($68.55M) | ($65.42M) | ($60.37M) | ($56.30M) | ($53.64M) | ($50.68M) | ($48.68M) | ($46.57M) | ($44.60M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.23M) | - | - | - | ($1.64M) | - | - | - | ($2.35M) | - |
| Investing Cash Flow | ($5.7K) | - | - | - | ($50.8K) | - | - | - | ($41.4K) | - |
| Financing Cash Flow | ($118.5K) | - | - | - | $1.03M | - | - | - | $2.02M | - |
| CapEx | $5.7K | - | - | - | $50.8K | - | - | - | $41.4K | - |
| Free Cash Flow | ($3.23M) | - | - | - | ($1.69M) | - | - | - | ($2.39M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -267.6% | - | -158.6% | -198.2% | -141.7% | - | -84.0% | -87.1% | -80.8% | - |
| EBITDA margin | -259.1% | - | -150.7% | -189.2% | -133.4% | - | -77.5% | -86.2% | -74.6% | - |
| Net margin | -268.6% | - | -349.3% | -319.9% | -143.5% | - | -85.1% | -88.0% | -81.5% | - |
| Free cash flow margin | -239.2% | - | - | - | -91.3% | - | - | - | -99.2% | - |
| FCF / Net income | 0.89 | - | - | - | 0.64 | - | - | - | 1.22 | - |
| R&D / Revenue | 25.9% | - | 22.9% | 24.5% | 19.8% | - | 11.7% | 16.8% | 16.4% | - |
| SG&A / Revenue | 239.8% | - | 152.8% | 174.4% | 132.3% | - | 100.6% | 103.1% | 90.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -45.7% | - | -43.7% | -85.5% | -48.0% | - | -30.5% | -31.7% | -24.4% | - |
| Return on equity | -99.2% | - | -56.7% | 190.1% | -184.8% | - | -64.1% | -61.5% | -37.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.36 | 2.60 | 3.65 | 0.64 | 0.55 | 0.87 | 1.02 | 1.15 | 2.22 | 1.77 |
| Quick ratio | 1.34 | 2.58 | 3.64 | 0.63 | 0.53 | 0.86 | 1.01 | 1.14 | 2.21 | 1.76 |
| Cash ratio | 0.97 | 2.22 | 3.25 | 0.31 | 0.13 | 0.36 | 0.30 | 0.34 | 1.38 | 1.26 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -245.7x | - | -427.9x | -240.5x | -111.6x | - | -91.3x | -1535.1x | -82.6x | - |
| Equity multiplier | 2.17 | 1.51 | 1.30 | -2.22 | 3.85 | 2.50 | 2.10 | 1.94 | 1.53 | 1.69 |
| Liabilities / Assets | 0.54 | 0.34 | 0.23 | 1.45 | 0.74 | 0.60 | 0.52 | 0.48 | 0.35 | 0.41 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.13 | 0.27 | 0.33 | - | 0.36 | 0.36 | 0.30 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -27.1% | - | -38.5% | -47.1% | -23.0% | - | 682.8% | 12047.4% | 261180.2% | - |
| Revenue CAGR (3y) | 1036.4% | - | 979.4% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -37.7% | - | -16.2% | -20.5% | -35.1% | - | 14.0% | -205.2% | -167.6% | - |
| Net income growth (YoY) | -36.5% | - | -152.4% | -92.4% | -35.6% | - | 12.7% | -21.3% | -33.3% | - |
| EPS growth (YoY) | -406.3% | - | -2862.5% | 10.5% | 20.0% | - | 86.3% | -533.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -91.0% | - | - | - | 29.1% | - | - | - | -258.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 154.4% | 179.7% | 185.2% | - | -72.6% | -46.4% | -55.4% | -57.6% | -45.6% | -56.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$12.32M totalLaboratory Services$6.16M · 50.0%
Health Care Patient Service$4.97M · 40.3%
Histology Service Fees$1.12M · 9.1%
Medical Director Fees$68.3K · 0.6%
Other Revenues$4.9K · 0.0%
Department Of Defense Observational Studies$577 · 0.0%
Diagnostic Research And Development$577 · 0.0%
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing bioAffinity Technologies against the 5 most active filers in the same SIC group.